Amended Current Report Filing (8-k/a)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION  

Washington, D.C. 20549

  

FORM 8-K/A

  (Amendment No.1 to Form 8-K)

CURRENT REPORT

  

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

  

Date of Report (Date of earliest event reported): July 9, 2020

  

BIOFORCE NANOSCIENCS HOLDINGS, INC.

 (Exact name of registrant as specified in its charter)

 

Nevada		000-51074		74-3078125
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)
		2020 General Booth Blvd. Suite 230 Virginia Beach, VA 23454 (Address of principal executive offices)

 

                   Registrant's telephone number: [phone]

                 Registrant’s fax number: [phone]

            ______________________________________

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

  

[ ]     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

[ ]     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

  

[ ]     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

  

[ ]     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

  

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2) Emerging growth company [X]
  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.[ ]

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [   ] No [X] 

 

EXPLANATORY NOTE

The amendment on FORM 8-K/A was done to correct a wrong word usage, replacing "formerly" with "formally" in Item 8.01.

 

-1-

ITEM 8.01 - OTHER INFORMATION

 

BioForce Nanosciences Holdings, Inc. formally entered into merger and acquisition talks with Element Global, Inc., a Utah Corporation which publicly trades under the symbol ELGL.

SIGNATURE  

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Amended report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

BIOFORCE NANOSCIENCES HOLDINGS, INC.

Date: July 9, 2020

 

By:/s/ Merle Ferguson

Name:  Merle Ferguson

Title:   CEO/ Chairman

-2-